pirtobrutinib (Jaypirca)
Jump to navigation
Jump to search
Indications
- chronic lymphocytic leukemia (CLL), including previously treated CLL[1]
Dosage
Adverse effects
- fatigue (20%), diarrhea (17%), contusion (13%)
- neutropenia in 10%, anemia in 4%
- abdominal pain, dyspnea, constipation, pyrexia each < 1%
Mechanism of action
- Bruton tyrosine kinase inhibitor (BTK inhibitor)
More general terms
References
- ↑ 1.0 1.1 Ingram I Pirtobrutinib Makes Splash as New CLL Drug Highly active in pretreated patients, even prior BTK inhibitor exposure, with little toxicity. MedPage Today March 8, 2021 https://www.medpagetoday.com/hematologyoncology/leukemia/91533
Mato AR et al Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021, Mar 6;397(10277):892-901 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33676628
Michot JM, Ribrag V. Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. Lancet 2021. Mar 6;397(10277):855-857. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33676615 - ↑ Ingram I Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. But no overall survival benefit seen in confirmatory trial. MedPage Today December 11, 2024 https://www.medpagetoday.com/meetingcoverage/ashhematology/113337